153 related articles for article (PubMed ID: 37229833)
1. A prodrug of the capsid assembly modulator improved druggability and lowing HBsAg and HBeAg for the treatment of chronic hepatitis B.
Chen W; Gong Y; Long G; Wang X; Yang Y; Liu J; Li H; Tong X; Zhao Q; Yang L; Zuo J; Hu Y
Eur J Med Chem; 2023 Sep; 257():115485. PubMed ID: 37229833
[TBL] [Abstract][Full Text] [Related]
2. Class A capsid assembly modulator apoptotic elimination of hepatocytes with high HBV core antigen level
Berke JM; Tan Y; Sauviller S; Wu D-t; Zhang K; Conceição-Neto N; Blázquez Moreno A; Kong D; Kukolj G; Li C; Zhu R; Nájera I; Pauwels F
J Virol; 2024 Mar; 98(3):e0150223. PubMed ID: 38315015
[TBL] [Abstract][Full Text] [Related]
3. Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle.
Lahlali T; Berke JM; Vergauwen K; Foca A; Vandyck K; Pauwels F; Zoulim F; Durantel D
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012770
[TBL] [Abstract][Full Text] [Related]
4. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
[TBL] [Abstract][Full Text] [Related]
5. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
6. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment.
Wang X; Chi X; Wu R; Xu H; Gao X; Yu L; Liu L; Zhang M; Tan Y; Niu J; Jin Q
Virol J; 2021 Jan; 18(1):4. PubMed ID: 33407619
[TBL] [Abstract][Full Text] [Related]
7. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
Li J; Sun X; Fang J; Wang C; Han G; Ren W
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
[TBL] [Abstract][Full Text] [Related]
8. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
9. State-of-the-art and emerging antivirals for chronic hepatitis B infection.
Papatheodoridi M; Papatheodoridis GV
Expert Opin Pharmacother; 2022 Dec; 23(18):1999-2012. PubMed ID: 36329612
[TBL] [Abstract][Full Text] [Related]
10. A novel phthalazinone derivative as a capsid assembly modulator inhibits hepatitis B virus expression.
Yang L; Gong Y; Liu F; Chen W; Wang X; Long G; Li H; Xiao F; Lu M; Hu Y; Tong X; Zuo J
Antiviral Res; 2024 Jan; 221():105763. PubMed ID: 38008192
[TBL] [Abstract][Full Text] [Related]
11. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
12. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
13. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus.
Berke JM; Dehertogh P; Vergauwen K; Van Damme E; Mostmans W; Vandyck K; Pauwels F
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584155
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
[TBL] [Abstract][Full Text] [Related]
15. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
16. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
17. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
Demirören K; Kocamaz H; Doğan Y
Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
[TBL] [Abstract][Full Text] [Related]
18. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
Lu HY; Zhuang LW; Yu YY; Si CW; Li J
Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
[TBL] [Abstract][Full Text] [Related]
19. HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients.
Yang J; Chen J; Ye P; Jin L; Wu W; Sheng G; Li LJ
J Transl Med; 2014 Jun; 12():183. PubMed ID: 24962263
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
Chen J; Wang Z; Zhou B; Wang Y; Hou J
Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
